Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:TOVX 16 October 2025 - 24 October 2025

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva shares surged 92% intraday Oct. 15 after its VCN-01 therapy met primary endpoints in a Phase 2b pancreatic cancer trial, then fell back following a $4 million equity raise. Median survival in a two-dose subgroup reached 14.8 months versus 11.6 for chemo alone. The company held $12.1 million cash as of June 30, 2025, funding operations into early 2026. Expanded trial results will be presented at ESMO Oct. 20.
24 October 2025
·

Stock Market Today

  • Tourmaline Oil Issues CA$250 Million 2031 Notes: Investor Implications
    March 22, 2026, 5:03 AM EDT. Tourmaline Oil Corp. raised CA$250 million through senior unsecured notes due 2031, with a fixed 3.934% coupon and a provisional BBB (High) credit rating. The proceeds aim to refinance debt and fund general corporate needs, aligning with its CA$1.75 billion net debt target and balance sheet discipline. While extending debt maturities supports Tourmaline's long-term capital strategy, investors must monitor risks from its heavy natural gas exposure and significant Montney and LNG-linked project spending. The notes fit into a broader investment narrative centered on steady growth, capital control, and cash flow resilience amid fluctuating gas prices. Current fair value estimates cluster between CA$67.04 and CA$72.00, reflecting cautious optimism about the company's funding flexibility and long-term prospects.
Go toTop